Article Dans Une Revue Neurology Neuroimmunology & Neuroinflammation Année : 2025

Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis

1 ARENES - Arènes: politique, santé publique, environnement, médias
2 RSMS - Recherche sur les services et le management en santé
3 EHESP - École des Hautes Études en Santé Publique [EHESP]
4 METIS - Département Méthodes quantitatives en santé publique
5 HCL - Hospices Civils de Lyon
6 CRNL - Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
7 OFSEP - Observatoire Français de la Sclérose En Plaques [Lyon]
8 UCBL - Université Claude Bernard Lyon 1
9 CHU - Hôpital Pasteur [Nice]
10 CHU Nice - Centre Hospitalier Universitaire de Nice
11 Service de Neurologie [CHRU Besançon]
12 Service de Neurologie [CHU Rennes]
13 CHU Amiens-Picardie
14 CHU Rouen
15 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
16 CHU Clermont-Ferrand
17 CRC-SEP Auvergne - Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Clermont-Ferrand]
18 Neuro-Dol - Neuro-Dol
19 BMNST - Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques
20 Centre d’Investigation Clinique Plurithématique (CIC - P) - CIC Strasbourg
21 CHU Caen
22 Hôpital Bretonneau
23 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
24 Centre Hospitalier de Saint-Denis [Ile-de-France]
25 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
26 Service de Neurologie [Rennes] = Neurology [Rennes]
27 CIC - Centre d'Investigation Clinique [Rennes]
28 Hôpital Dupuytren [CHU Limoges]
29 CHU Pitié-Salpêtrière [AP-HP]
30 Centre Hospitalier de Gonesse
31 CHU Dijon
32 CEP - Centre d'épidémiologie des populations
33 CHU Reims - Hôpital universitaire Robert Debré [Reims]
34 Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM]
35 Höpital NOVO
36 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
37 U1215 Inserm - UB - Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale
38 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
39 ICM - Institut du Cerveau = Paris Brain Institute
40 Pôle NIRR - Service de Neurologie [CHU Nimes]
41 IGF - Institut de Génomique Fonctionnelle
42 Hôpital Henri Mondor
43 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
44 CRC-SEP Nord-Pas de Calais - Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille]
45 LilNCog - Lille Neurosciences & Cognition - U 1172
46 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
47 U1064 Inserm - CR2TI - Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology
Eric Berger
Anne Kerbrat
Abdullatif Al Khedr
Bertrand Bourre
Gilles Defer
Ines Doghri
Laurent Magy
Elisabeth Maillart
Corinne Pottier
  • Fonction : Auteur
Abir Wahab

Résumé

Background and objectives: Older studies reported an increased risk of relapse after in vitro fertilization (IVF) in women with multiple sclerosis (MS), which has not been confirmed by more recent works. All these studies had several limitations, such as small sample sizes, absence of a control population, or lack of neurologic validation of the relapses. The aim of this study was to determine the risk of relapse after IVF in women with MS. Methods: This retrospective cohort study included all women with MS who underwent IVF between 2009 and 2019 and a control group of women with MS who did not undergo IVF matched on age, MS duration, number of relapses, and MS-specific treatments in the previous year. Data on MS (disease duration, treatments, and relapses) were from the French MS Registry (OFSEP), whereas data on IVF (number of procedures, stimulation protocol type, and outcomes) were from the French national health insurance database. For this, the 2 databases were linked by indirect matching. Results: In total, 115 women with MS underwent 199 IVF procedures (mean age at first IVF: 33.9 ± 4.0 years; 45.2% had ≥2 IVF procedures), and 175 IVFs (88.0%) could be matched to specific patients. The risk of relapse in the 3 months after index date was the same in both IVF group and control group (0.06 relapse per patient-year), as confirmed also by the before-after analysis in the IVF group (0.06 vs 0.08). Discussion: This study, using a 10-year clinical and administrative dataset, did not find any increased risk of relapse after IVF. The maintenance of disease-modifying therapies until IVF was a determining factor in reducing the risk of relapse.
Fichier principal
Vignette du fichier
mainguy.pdf (449) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04947771 , version 1 (14-02-2025)

Licence

Identifiants

Citer

Marie Mainguy, Romain Casey, Sandra Vukusic, Christine Lebrun-Frenay, Eric Berger, et al.. Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation, 2025, 12 (2), pp.e200371. ⟨10.1212/NXI.0000000000200371⟩. ⟨hal-04947771⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More